A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.

Saved in:
Bibliographic Details
Title: A phase III randomized crossover trial of plerixafor versus G-CSF for treatment of WHIM syndrome.
Authors: McDermott DH; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases., Velez D; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases., Cho E; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases., Cowen EW; Dermatology Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases., DiGiovanna JJ; Laboratory of Cancer Biology and Genetics and., Pastrana DV; Laboratory of Cellular Oncology, National Cancer Institute., Buck CB; Laboratory of Cellular Oncology, National Cancer Institute., Calvo KR; Department of Laboratory Medicine, Clinical Center., Gardner PJ; Office of the Clinical Director, National Institute of Dental and Craniofacial Research., Rosenzweig SD; Department of Laboratory Medicine, Clinical Center., Stratton P; National Institute of Neurologic Disorders and Stroke., Merideth MA; Office of the Clinical Director, National Human Genome Research Institute., Kim HJ; Otolaryngology Branch, National Institute on Deafness and other Communication Disorders, and., Brewer C; Otolaryngology Branch, National Institute on Deafness and other Communication Disorders, and., Katz JD; Rheumatology Fellowship and Training Branch, National Institute of Arthritis and Musculoskeletal and Skin Diseases, NIH, Bethesda, Maryland, USA., Kuhns DB; Leidos Biomedical Research Inc., Frederick, Maryland, USA., Malech HL; Laboratory of Clinical Immunology and Microbiology and., Follmann D; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA., Fay MP; Biostatistics Research Branch, National Institute of Allergy and Infectious Diseases, NIH, Bethesda, Maryland, USA., Murphy PM; Laboratory of Molecular Immunology, National Institute of Allergy and Infectious Diseases.
Source: The Journal of clinical investigation [J Clin Invest] 2023 Oct 02; Vol. 133 (19). Date of Electronic Publication: 2023 Oct 02.
Publication Type: Randomized Controlled Trial; Clinical Trial, Phase III; Journal Article; Research Support, N.I.H., Intramural; Research Support, N.I.H., Extramural
Journal Info: Publisher: American Society for Clinical Investigation Country of Publication: United States NLM ID: 7802877 Publication Model: Electronic Cited Medium: Internet ISSN: 1558-8238 (Electronic) Linking ISSN: 00219738 NLM ISO Abbreviation: J Clin Invest Subsets: MEDLINE
Database: MEDLINE Ultimate
Description
ISSN:1558-8238
DOI:10.1172/JCI164918